Li 2016.
Methods | SIngle‐centre Non‐inferiority comparison of mEOX vs FOLFIRI RCT 2 arms: modified EOX vs FOLFIRI |
|
Participants | 105 patients (55 received EOX, 50 received FOLFIRI) | |
Interventions | "The EOX group was given epirubicin 50 mg/m2 iv on day one, oxaliplatin 85 mg/m2 iv on day 1 and capecitabine at a twice‐daily dose of 625 mg/m2 po for 2 wk, which was repeated every 3 wk" | |
Outcomes | OS PFS (separately for both first‐ and second‐line) Objective response rate Disease control rate Adverse events |
|
Notes | Second‐line chemo allowed | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Not specified |
Allocation concealment (selection bias) | Unclear risk | Not mentioned |
Incomplete outcome data (attrition bias) efficacy | Unclear risk | Patient disposition/CONSORT flow diagram not provided; unclear how many were screened and excluded, and for what reasons |
Incomplete outcome data (attrition bias) safety | Unclear risk | Patient disposition/CONSORT flow diagram not provided; unclear how many were screened and excluded, and for what reasons |
Selective reporting (reporting bias) | Unclear risk | Adverse effects (NCI‐CTC) categorised and analysed as grades 1‐4 and 3‐4 |
Other bias | Unclear risk | N/A |
Blinded review of CT/MRI‐scans? | Unclear risk | Not mentioned |